Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Advanced Or Metastatic Non-Small Cell Lung Cancer Study In Patients Who Have Received One Platinum-based Chemotherapy
This study is currently recruiting patients.
Sponsored by: | GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
Purpose
Purpose of study is to determine how effective and safe a new investigational drug is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously (IV), repeated once every 21 days. A patient may continue treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times over 24 hr period to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for routine lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment.
Condition | Treatment or Intervention | Phase |
---|---|---|
Non-small cell lung cancer |
Drug: Investigational Cancer Drug |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Lung Cancer; Respiratory Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |